X0202 SCHEDULE 13G 0002115022 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 03/31/2026 0001472012 Immunome Inc. 45257U108 18702 N. Creek Parkway Suite 100 Bothell WA 98011 Rule 13d-1(b) Sirenia Capital Management LP b DE 0.00 6895000.00 0.00 6895000.00 6895000.00 N 6.1 IA PN Alex Silverstein b X1 0.00 6895000.00 0.00 6895000.00 6895000.00 N 6.1 HC IN Immunome Inc. 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011 This statement is filed by: (i) Sirenia Capital Management LP ("Sirenia") with respect to the common stock, par value $0.0001 per share ("Common Stock"), of Immunome, Inc. (the "Issuer") held by an investment fund (the "Sirenia Fund") and managed account (the "Sirenia Account") it manages; and (ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Common Stock held by the Sirenia Fund and Sirenia Account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act"). The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139. Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 113,133,199 shares of Common Stock outstanding as of February 27, 2026, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 3, 2026. 6.1% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Sirenia Capital Management LP /s/ Kolby Loft 05/15/2026 Alex Silverstein /s/ Alex Silverstein 05/15/2026 Exhibit 99.1: Joint Filing Agreement